Introduction
In the United States, lung cancer is the leading cause of cancer deaths among both men and women, and more patients will die of lung cancer than breast, colon and prostate combined (Jemal et al., 2006 ). An estimated 174 000 new diagnoses and 162 000 deaths are expected from lung cancer in the United States in 2006 (Jemal et al., 2006) . Approximately 85% of patients will have the non-small-cell histology, and approximately 55% of patients will present with locally advanced or metastatic disease (Bulzebruck et al., 1992; Govindan et al., 2006) . The current standard treatment for patients with preserved functional status is double-agent cytotoxic chemotherapy (Pfister et al., 2004) . The median survival with chemotherapy treatment is 8-10 months, and the 1-year survival rate is 20-30% (Schiller et al., 2002) . The addition of a third cytotoxic agent does not appear to improve survival, and a therapeutic plateau has been reached with cytotoxic therapy (Delbaldo et al., 2004) .
Because of the relatively poor prognosis of patients with advanced-stage disease, there has been great interest in developing new therapeutic strategies, especially the development of antiangiogenesis therapy. Angiogenesis, the process where tumors develop new blood supply, is essential for solid tumor growth beyond 2-3 mm 3 (Folkman, 1992) . Complex interactions involving numerous inhibitory or stimulatory factors contribute to the careful regulation of angiogenesis. When the stimulatory factors exceed the inhibitory factors an 'angiogenic switch' occurs, and a cascade of events is initiated, including the release of proangiogenic stimulatory factors, endothelial cell activation, endothelial cell migration, proliferation and capillary tube formation (Herbst et al., 2005b) . Solid tumors develop the ability to secrete proangiogenic factors which lead to continued angiogenesis and metastases (Folkman, 1990; Herbst et al., 2005b) .
The vascular endothelial growth factors, VEGF-A (also known as VEGF), VEGF-B and VEGF-C, are proangiogenic factors that play a critical role in the development of non-malignant and malignant angiogenesis, and the proliferation and maintenance of vasculature (Robinson and Stringer, 2001) . VEGF is the most active in the development of tumor angiogenesis and metastasis. VEGF binds to VEGFR-1 (also known as Flt-1), which mediates angiogenesis, and to VEGFR-2 (also known as KDR), which mediates lymphangiogenesis and angiogenesis (Ferrara et al., 2003) . VEGF has been associated with the development hyperpermeable, immature vasculature, which is typical of malignancy-related angiogenesis (Dvorak et al., 1995; Bates et al., 2001; Ferrara et al., 2003) . VEGFR receptors are expressed on lung cancer cells and mediate antiapoptotic and metastatic signals; therefore, antiangiogenic therapy may have direct tumor effects as well (Dy and Adjei, 2006) . VEGF may play a significant role in the development of inflammation and other processes frequently associated with malignancy. VEGF is also known as vascular permeability factor, and can induce vascular leakage and may be involved brain edema (Ferrara et al., 2003) . Malignant pleural effusions from lung cancer have high levels of VEGF, and VEGF secretion has also been associated with the development of ascites (Senger et al., 1983; Yanagawa et al., 1999; Yano et al., 2000a) . The direct role VEGF has in angiogenesis and other malignant processes made it an attractive target for the development of new therapeutic agents.
The role of angiogenesis in the progression of lung cancer is well established, with multiple studies revealing that high microvessel density is associated with the development of metastases and poor survival (Fontanini et al., 1995; Lucchi et al., 1997; D'Amico et al., 1999; Yano et al., 2000b) . High vascularity has also been associated with tumor progression (Ushijima et al., 2001) . The preclinical data on the role of angiogenesis in the behavior of lung cancer supported the development of clinical trials of antiangiogenesis agents. There are currently multiple different agents, with antiangiogenic activity being investigated in non-small-cell lung cancer (NSCLC), however, the only agent currently approved by the United States Food and Drug Administration is bevacizumab. Bevacizumab is a recombinant humanized monoclonal antibody that binds to the circulating VEGF-A ligand.
Bevacizumab as a single agent has limited activity, and in the clinical phase I trial in patients with solid tumors, and no responses were seen in 23 patients evaluable for response; however, 12 patients had stable disease over the duration of the study . Thus, bevacizumab as a single agent appears to be cytostatic; however, treatment with bevacizumab is synergistic with chemotherapy. In a pivotal phase III trial in patients with metastatic colorectal cancer, patients treated with chemotherapy in combination with bevacizumab had superior survival to patients treated with the same chemotherapy (Hurwitz et al., 2004) . The synergistic effects of bevacizumab with chemotherapy have been attributed to a reduction in vascular permeability with normalization of the vasculature resulting in a reduction of interstitial pressure within the tumor (Jain, 2001) . These changes are believed to enhance the delivery of cytotoxic therapy to the malignant cells (Jain, 2001) .
Bevacizumab in the treatment of lung cancer
A phase I trial in patients with solid tumors indicated that bevacizumab could be safely combined with fulldose carboplatin and paclitaxel, and the efficacy and safety of bevacizumab was investigated in a randomized phase II trial in patients with advanced or recurrent NSCLC Johnson et al., 2004) . Ninety-nine patients were randomized to one of three treatment arms: carboplatin (area under the curve (AUC) ¼ 6 mg/ml/min) using the Calvert equation (Calvert et al., 1989) and paclitaxel (200 mg/m 2 ) every 3 weeks alone or with low or high bevacizumab (7.5 or 15 mg/kg every 3 weeks, respectively) . After completing the planned chemotherapy on the bevacizumab containing arms, non-progressing patients could continue the bevacizumab at the same dose and schedule for up to a maximum of 18 doses. Patients on all three arms received a median of six cycles of carboplatin and paclitaxel, and patients on the lowdose and high-dose bevacizumab arm received a median of eight and 10 doses of bevacizumab, respectively. Treatment with bevacizumab (15 mg/kg) resulted in a higher response rate, a longer median time to progression and a trend towards increased survival ( Table 1) . The difference in median time to tumor progression was statistically significant between the high-dose bevacizumab arm and control arm (7.4 versus 4.2 months, respectively; P ¼ 0.023), but no difference was seen between the low-dose bevacizumab and control treatment arm (4.3 versus 4.2 months, respectively; P ¼ nonsignificant).
The combination of bevacizumab with chemotherapy was notable for several bevacizumab-associated adverse events, including hypertension, proteinuria and bleeding. Two distinct clinical patterns of bleeding were observed: minor mucocutaneous hemorrhage, predominantly epistaxis and major hemoptysis. Six patients experienced a major life-threatening bleeding described as hemoptysis or hematemesis, and four events were fatal. Four of the 13 patients (30%) with squamous histology treated with bevacizumab experienced severe hemorrhage versus two of 54 (4%) patients with nonsquamous histology. Five of the six cases had cavitation at baseline or tumor necrosis at baseline or during therapy. Pulmonary hemorrhage may have been associated with central location. However, many squamous cell carcinomas are centrally located; thus location may have been a surrogate marker for histology. The episodes of pulmonary hemorrhage did not appear to be dose dependent because five of the six patients were Bevacizumab in the treatment of NSCLC TE Stinchcombe and MA Socinski on the low-dose arm, or time dependent because the events occurred early (p60 days) and late (X180 days). If a subset analysis is performed excluding the squamous histology patients, it suggests that bevacizumab therapy improves response, time to tumor progression and overall survival (Table 1) . Based on the results of this phase II trial, the Eastern Cooperative Oncology Group (ECOG) initiated a phase II/III trial, ECOG 4599, comparing carboplatin, paclitaxel versus carboplatin, paclitaxel, bevacizumab (15 mg/kg) in chemotherapy-naı¨ve patients with nonsquamous histology and advanced-stage IIIB/IV disease . Patients with a history of gross hemoptysis (defined as >1/2 a teaspoon of bright red blood), central nervous system metastases or history of thrombotic disorder or hemorrhagic disorders were excluded. Patients were required to have a computed tomography (CT) scan of the head within 4 weeks of enrollment to evaluate for brain metastases. Patients with central tumors were not excluded.
The bevacizumab-containing treatment arm in comparison to the standard chemotherapy arm had a statistically significant higher rate of National Cancer Institute (NCI) Common Terminology Criteria for Adverse Events (CTCAE) grade 4 neutropenia (25.5 versus 16.8%, respectively; P ¼ 0.002), thrombocytopenia (1.6 versus 0.2%, respectively; P ¼ 0.04), and febrile neutropenia (5.2 versus 2%, respectively; P ¼ 0.02) (Sandler et al., 2006a) . There was a higher rate of non-hematologic toxicity on the bevacizuamab arm in comparison to the standard chemotherapy arm as well including grade 3-5 hypertension (7.7 versus 0.7%, respectively; Po0.001), hemorrhage (4.4 versus 0.7%, respectively; Po0.001) and proteinuria (3.1 versus 0%, respectively; Po0.001) . There were seven hemorrhage-related deaths on the bevacizumab arm versus one on the carboplatin and paclitaxel arm. The hemorrhage-related deaths on the bevacizumab-related arm consisted of hemoptysis (n ¼ 5) and gastrointestinal bleeding (n ¼ 2). There were 15 treatment-related deaths on the bevacizumab-treatment arm versus two on the standard treatment arm; the difference was significant (P ¼ 0.001).
There was a statistically significant improvement in the response, progression free survival, and overall survival in the bevacizumab-containing arm (Table 2 ). An exploratory subgroup analysis was performed investigating the efficacy of bevacizumab with regard to age, stage, prior weight loss, race, performance status and gender. Survival was seen across all groups except for gender . No survival benefit was seen among women despite a fourfold increase in response and statistically significant difference in progression-free survival (Table 3) . The test for treatment sex interaction in a proportional hazards model for survival was statistically significant (P ¼ 0.04). The reasons for this difference are unclear, and there were no survival differences seen in the previous trial of bevacizumab in metastatic colorectal cancer (Hurwitz et al., 2004) . Until the potential relationship between gender and overall survival can be better clarified female patients should not be denied therapy with bevacizumab. A retrospective analysis of the episodes of pulmonary hemorrhage occurring o150 days from initiation of treatment on the phase II and III trials was performed. This analysis used a match case-control method to identify potential radiographic and clinical risk factors for severe pulmonary hemorrhage (Sandler et al., 2006b ). This analysis identified hemoptysis at baseline, and tumor cavitation as probable risk factors for pulmonary hemorrhage; however, central location was not a risk factor. The number of episodes of hemoptysis included in this analysis was small (n ¼ 6), and a larger analysis which includes patients from ongoing clinical trials will be needed to better determine the pretreatment and treatment-related risk factors and the relative risk associated with each factor.
In addition to these completed clinical trials, an ongoing phase III trial in advanced NSCLC, the AVAiL, is investigating bevacizumab in combination with cisplatin and gemcitabine. This three-arm trial will enroll 1050 patients: the control arm is cisplatin and gemcitabine, and the two experimental arms are cisplatin and gemcitabine in combination with bevacizumab 7.5 mg/kg, and 15 mg/kg every 3 weeks. The primary end point will be progression-free survival, and this trial will provide valuable safety and efficacy information about bevacizumab at two different doses, and in combination with a different chemotherapy regimen. The safety and efficacy data from this trial should be available in the next year.
Second-line trials
Two phase II trials have investigated the role of bevacizumab in patients with non-squamous histology who have progressed after initial chemotherapy Bevacizumab in the treatment of NSCLC TE Stinchcombe and MA Socinski treatment. Neither of these trials included patients who had received bevacizumab therapy in the first-line therapy. A phase I/II trial investigated the toxicity and efficacy of bevacizumab in combination with erlotinib, an oral epidermal growth factor (EGFR) tyrosine kinase inhibitor (TKI) in patients who had progressed after initial chemotherapy for NSCLC (Herbst et al., 2005a) . Forty patients were enrolled in the trial, and 22 of the patients (55%) had received Xtwo prior chemotherapy regimens, and nine patients were never smokers (22.5%), which has been associated with higher response to EGFR TKI therapy (Pao et al., 2004) . No doselimiting toxicities were observed in the phase I portion, and the phase II dose was established as erlotinib 150 mg daily and bevacizumab 15 mg/kg every 3 weeks. The most common toxicities observed were rash, diarrhea, infection, hematuria and proteinuria. No treatmentrelated deaths were reported, and the only grade 3 or 4 toxicities seen were rash (6%) and infection (6%). This combination demonstrated significant activity. Eight patients (20%) had a partial response (PR), and 26 patients (65%) had stable disease (SD) as their best response. The median overall survival for the 34 patients treated at the phase II dose was 12.6 months, and the progression-free survival was 6.2 months. Two (22%) of the nine patients who had never smoked had a PR. EGFR mutations have been associated with response to EGFR TKI therapy (Lynch et al., 2004; Paez et al., 2004; Pao et al., 2004) , and nine patients had sufficient paraffin-embedded tissue for EGFR mutational analysis. These nine patients included three patients with a PR and three patients with SD, and three with progressive disease (PD). Mutations were detected in one of the three patients with a PR, and one of the three with SD.
A second randomized phase II trial was performed in the second-line setting to investigate the safety and efficacy of bevacizumab with chemotherapy or erlotinib versus standard chemotherapy (Fehrenbacher et al., 2006) . Patients were required to have an ECOG performance status of 0-2 and non-squamous histology. Patients with central lesions, cavitation or lesion proximal to a major blood vessel were excluded. Other inclusion and exclusion criteria were similar to the criteria used for ECOG 4599. One hundred and twenty patients were randomized to one of three treatment arms: chemotherapy (docetaxel or pemetrexed) alone, bevacizumab and chemotherapy (docetaxel or pemetrexed) or bevacizumab and erlotinib. There was a trend towards improved progression-free survival with the addition of bevacizumab and chemotherapy (HR ¼ 0.66; 95% CI 0.38-1.16) and bevacizumab and erlotinib (HR ¼ 0.72; 95% CI 0.42-1.23) in comparison to chemotherapy alone, however, the progression-free survival and overall survival did not reach statistical significance. The preliminary safety data indicate a rate of grade 3-5 hemorrhage 5.1%, and the overall rate of neutropenia was similar between the chemotherapy treatment arms. This randomized phase II trial provides valuable safety data about bevacizumab in the secondline setting, and the trend towards improved progression-free survival is intriguing. However, due to the trial design, it cannot be definitively determined if treatment with a bevacizumab-containing treatment results in superior survival to standard therapy.
Patient populations excluded from the ECOG 4599 trial
Owing to the inclusion and exclusion criteria used, a significant percentage of the advanced NSCLC population was excluded from the ECOG 4599 trial. On a recent North American trial of advanced NSCLC, 17% of patients presented with brain metastases, and there is evidence that the prevalence of brain metastases is increasing on cooperative group trials (Treat et al., 2005; Wakelee et al., 2006a) . Previously, brain imaging was only performed in patients with advanced disease if there was a clinical suspicion of brain metastases (Pfister et al., 2004) . Since the presence of brain metastases will determine if a patient is a candidate for bevacizumab therapy, brain imaging will probably be performed more frequently, and the prevalence of brain metastases may increase. Magnetic resonance imagining (MRI) is more sensitive than CT scans, and increase use of MRI may lead to an increase in the prevalence of brain metastases as well (Schellinger et al., 1999) .
The exclusion of patients with brain metastases was based on a single episode of central nervous hemorrhage related to brain metastases on the phase I trial . Given the prevalence of brain metastases and the limited safety data of bevacizumab, there is significant interest in investigating the safety of bevacizumab in this patient population. A phase II trial of bevacizumab in combination with first-or second-line therapy in patients with treated brain metastases from non-squamous NSCLC (known as the PASSPORT trial) has been initiated. The interval between completion of radiation therapy for the brain metastases and initiation of the bevacizumab therapy cannot be less than 4 weeks. The systemic therapy used will be at the discretion of the investigator. The primary end point for this study is the incidence of NCI grade X2 central nervous system hemorrhage, and secondary objectives will be overall survival and toxicity. This trial will enroll approximately 100 patients at 30 centers.
There is also interest in determining, if patients with squamous histology can be risk stratified for the development of hemoptysis based on clinical or radiographic factors so that not all patients with squamous histology will be excluded. The prevalence of the squamous histology on recent ECOG cooperative group trials is estimated to be approximately 20% of patients (Wakelee et al., 2006a) . The current hypothesis is that bevacizumab therapy induces central necrosis or causes enlargement of a pre-existing cavitation. This event in combination with poorly developed and immature vessels of the tumor may result in hemorrhage into the tumor cavity . Thoracic radiation therapy (TRT), a standard therapy for hemoptysis, may reduce the risk of patients developing serious pulmonary hemorrhage. A clinical trial to investigate treatment with bevacizumab in patients with squamous histology after TRT is in development. Another phase II trial, the BRIDGE trial, will treat patients with squamous cell histology with two cycles of carboplatin and paclitaxel for two cycles, and then initiate treatment with carboplatin, paclitaxel and bevacizumab for an additional four cycles. Bevacizumab will be continued until disease progression, unacceptable toxicity or a maximum of 12 months of therapy. The hypothesis being tested is that tumor cavitation from rapid response to bevacizumab in combination with chemotherapy may have been a contributing factor for the development of pulmonary hemorrhage, and that prior treatment with chemotherapy or TRT will result in a more gradual response and patients will be at a lower risk of pulmonary hemorrhage. Until the safety data from these clinical trials are available, patients with squamous histology should not receive bevacizumab therapy. One clinical scenario where patients with squamous histology may have acceptable risk with bevacizumab therapy is if the patient has had surgical resection of all their intrathoracic disease, and upon relapse the metastatic disease is entirely extrathoracic.
Duration of therapy and integration into current treatment paradigms
The optimal duration of bevacizumab therapy is another clinical question as patients continued bevacizumab until disease progression on the ECOG 4599 trial. Treatment with single-agent bevacizumab may cause regression of vasculature, and the inhibition of neo-vascularization which theoretically would have cytostatic effects on tumor growth and increase the progression-free survival. Clinical evidence of activity of single-agent bevacizumab in NSCLC is limited, however, some data are available from the randomized phase II trial . Patients who were treated with carboplatin and paclitaxel could receive single-agent bevacizumab upon disease progression. Nineteen patients received second-line therapy with single agent bevacizumab, and five patients had stable disease. The median survival in this subgroup of patients was 10 months, and the 1-year survival rate was 47% from the time of crossing over. Some of the concerns about continued therapy with bevacizumab are the potential development of resistance to bevacizumab, and the longer duration of treatment potentially increases the risk for developing treatment-related complications. It is also possible that the majority of the benefit of bevacizumab therapy may be obtained in a defined duration of therapy, and continuous therapy is not necessary. The inconvenience, the expense and the fact that the single agent response rate of bevacizumab is low are also factors that need to be considered.
Another vexing clinical question is whether patients who progressed on single-agent bevacizumab therapy should be considered 'resistant' to bevacizumab, and should not receive bevacizumab in the second-line setting. The activity of bevacizumab in combination with standard second-line therapies after previous treatment with bevacizumab is currently unknown. ECOG has proposed a randomized phase II trial that will randomize patients upon disease progression to second-line chemotherapy alone or second-line chemotherapy and bevacizumab. Patients will be required to have received first-line chemotherapy with four to six cycles of platinum-based therapy and bevacizumab until disease progression.
Based on the promising results of phase II trials with the combination of bevacizumab and erlotinib, the integration of the combination into first-line therapy is being investigated in a randomized phase III trial, the ATLAS trial. All patients will receive four cycles of platinum-based therapy, carboplatin in combination with paclitaxel, docetaxel or gemcitabine, in combination with bevacizumab, and patients will be randomized to therapy with bevacizumab alone versus bevacizumab and erlotinib until disease progression. Patients, who progress on the bevacizumab alone arm, will receive erlotinib. The primary end point will be progression-free survival, and the secondary end points will be overall survival, response rate and safety.
Adjuvant therapy and therapy for unresectable stage III disease
Given the improvement in survival seen in advancedstage disease, there is interest in integrating bevacizumab into the treatment of early or locally advanced stage disease, and potentially improving the overall survival. Recent trials have revealed a survival benefit to cisplatin-based adjuvant therapy, and there is significant interest in improving the efficacy of adjuvant therapy (Arriagada et al., 2004; Douillard et al., 2005; Winton et al., 2005) . A United States Intergroup trial, ECOG 1505, has been developed that will compare cisplatinbased therapy versus cisplatin-based therapy in combination with bevacizumab in patients with resected stage IB (with tumors X4 cm), stage II and stage III disease (Wakelee et al., 2006b) . The chemotherapy must be cisplatin-based, however, the second agent will be docetaxel, gemcitabine or vinorelbine at the discretion of the treating physician, and patients on the bevacizumab treatment arm will receive bevacizumab for 1 year. The target accrual for this trial will be 1500 patients.
A multi center phase I/II trial investigating the role of bevacizumab in the treatment of patients with unresectable stage IIIA/B disease who are appropriate candidates for combined modality therapy is being coordinated by the University of North Carolina. Patients with squamous histology are eligible, but patients with squamous histology that abut or invade major blood vessels will be excluded. Other inclusion and exclusion criteria are similar to ECOG 4599. Patients will receive induction therapy with two cycles of carboplatin, paclitaxel and bevacizumab, and then will receive weekly carboplatin, paclitaxel and bi-weekly bevacizumab with concurrent TRT to 74 Gy. If the initial cohorts of patients have a tolerable toxicity profile, intermittent erlotinib with the TRT will be integrated in the treatment. The schedule of erlotinib is Tuesday through Friday during TRT, and the initial cohort will receive 50 mg daily. The final planned cohort on the trial will receive bevacizumab 10 mg/kg every 2 weeks and erlotinib 150 mg. After completion of the TRT, patients will receive consolidation therapy with bevacizumab 15 mg/kg every 3 weeks for six cycles and erlotinib 150 mg daily. The erlotinib will be discontinued at the end of the consolidation therapy. This trial will provide valuable information about the toxicity of bevacizumab and erlotinib in combination with TRT, additional toxicity data about patients with squamous histology, who are selected based on clinical and radiographic criteria, and the response rate of carboplatin, paclitaxel and bevacizumab in stage III disease.
The Southwest Oncology Group (SWOG) is also performing a phase I/II trial in patients with unresectable stage IIIA/B disease. All patients will receive cisplatin, etoposide and with TRT and docetaxel and bevacizumab consolidation therapy. Patients will receive growth stimulating factor (G-CSF) support during the consolidation therapy. Two cohorts of patients will receive bevacizumab, on different schedules, with cisplatin, and etoposide during the TRT. Patients with squamous histology and tumor cavitation or located within 1 cm of a major blood vessel will be excluded. The other inclusion and exclusion criteria are similar to the ECOG 4599 trial. The primary end point will be the rate of grade 4 or 5 hemorrhage, and the secondary end points will be progression-free survival, overall survival and response rate.
Predictors of response to Bevacizumab
The selection of the optimal dose of antiangiogenesis therapy and the predictors of response to therapy are areas of active investigation. In preclinical models, antiangiogenesis therapies generally result in disease stabilization or delay in disease progression (Ferrara et al., 2003) . The fact that these therapies are cytostatic means that a dose-response curve is unlikely to provide assistance in determining the optimal dose. Further complicating the issue is that the traditional paradigm of establishing the maximum tolerated dose based on doselimiting toxicities may not be applicable as many of these agents have limited acute toxicities (Adjei, 2006) . The most direct and accurate method of determining the optimal dose of antiangiogenetic therapy would be serial biopsies, however, given the risks associated with repeat biopsies, this approach is unlikely to be employed in lung cancer. The one clinical situation where this may be feasible is on a clinical trial investigating the use of preoperative antiangiogenesis therapy in early-stage disease.
This has led to the interest of in developing surrogate pharmacokinetic, pharmacodynamic, correlative science or radiological parameters of antiangiogenesis activity (Davis et al., 2003) . Plasma VEGF levels are one potential surrogate marker. A correlative science companion study of ECOG 4599 investigated elevated VEGF levels, basic fibroblast growth factor (bFGF), and soluble intracellular adhesion molecule-1 (ICAM) in NSCLC, and if there were changes in the levels in response to endothelial apoptosis . One hundred and sixty-six patients had pretreatment levels, and 112 patients had posttreatment levels. Only baseline ICAM level was significantly associated with response. Patients with low ICAM in both arms had a higher response rate than patients with a high ICAM (29 versus 13%, respectively; P ¼ 0.03), and better overall survival (P ¼ 0.00005), and 1 year survival (65 versus 25%, respectively). No other factor predicted survival. Tests for treatment interaction were significant for progression-free survival in the patients with low ICAM levels. This suggests baseline ICAM levels are prognostic for survival, and that improvements in progressionfree survival from the addition of bevacizumab occur mainly in patients with low ICAM levels.
The use of non-invasive radiological imaging has been investigated in a number of phase I trials of antiangiogenesis agents. A phase I trial of recombinant human endostatin (rh-Endo) investigated tumor blood flow and metabolism as measured on positron emission tomography (PET) (Herbst et al., 2002) . This trial found that tumor blood flow generally decreased with increasing doses of rh-Endo, however, the effects were complex and nonlinear. On a phase I trial with tetrathiomolybdate, an anticopper, antiangiogenic agent, a patient with rib metastases from renal cell carcinoma was evaluated with three-dimensional ultrasound which revealed a 4.4-fold decrease in tumor blood flow (Brewer et al., 2000) . A dynamic CT scan confirmed the decrease in blood flow (Brewer et al., 2000) . Another non-invasive method of assessing changes in tumor blood flow is dynamic contrast-enhanced magnetic resonance imaging (DCE-MRI). A significant correlation between changes in tumor vasculature and clinical outcome using this technology was detected on a phase I clinical trial of PTK787 (Morgan et al., 2003) . At this point, the preliminary data provide valuable information about the potential applications of these new technologies. However, these radiological markers will have to be correlated with clinical outcomes and validated in larger trials before they can be used in clinical decision making.
Conclusion
The ECOG 4599 trial demonstrated that the addition of bevacizumab to standard chemotherapy, carboplatin and paclitaxel resulted in a statistically significant and clinically relevant improvement in response rate, progression-free survival and overall survival. This pivotal trial provided confirmation of the concept that inhibition of angiogenesis would be an effective target for inhibiting disease progression in lung cancer. The carefully selected inclusion and exclusion criteria limited enrollment to patients who were at a lower risk for bevacizumab-related bleeding complications. However, even in this select patient population, there continued to be a statistically significant increased risk of grade 3-5 hemorrhage. Ongoing trials are evaluating the safety of bevacizumab in patient populations that were excluded from the ECOG 4599 trial. There is also significant interest in integrating bevacizumab therapy into earlier stage disease and second-line therapy. Bevacizumab is the first of several new antiangiogenic agents that will have activity in NSCLC.
